Related Experiment Video
Updated: Nov 7, 2025
09:16
High-sensitivity Detection of Micrometastases Generated by GFP Lentivirus-transduced Organoids Cultured from a Patient-derived Colon Tumor
Published on: June 14, 2018
10.3K
Detection of Circulating Gastrointestinal Cancer Cells in Conditionally Reprogrammed Cell Culture
Chun-Seok Yang1, In-Hwan Kim1, Hyun-Dong Chae1
1Department of General Surgery, Medical School, Daegu Catholic University Medical Center, Daegu, Republic of Korea.
In Vivo (Athens, Greece)
|April 29, 2021
Summary
This study explored detecting circulating tumor cells (CTCs) in gastrointestinal cancer patients using conditionally reprogrammed cell (CRC) culture. The CRC method showed potential for evaluating metastatic cancer cells in blood samples.
Area of Science:
- Oncology
- Cell Biology
- Molecular Diagnostics
Background:
- Gastrointestinal cancers pose significant health challenges.
- Detecting circulating tumor cells (CTCs) is crucial for monitoring cancer metastasis.
- Novel methods for CTC detection are needed.
Purpose of the Study:
- To detect circulating tumor cells (CTCs) in peripheral blood of gastrointestinal cancer patients.
- To evaluate the efficacy of conditionally reprogrammed cell (CRC) culture for CTC detection.
- To characterize cultured cells for specific cancer markers.
Main Methods:
- Blood samples (5 ml) were collected from 81 gastrointestinal cancer patients.
- Mononuclear cells were cultured for 4 weeks under conditionally reprogrammed cell (CRC) conditions.
- Cultured cells were analyzed using RT-PCR for hTERT and MAGE A1-6 mRNA expression.
Main Results:
- The CRC method demonstrated a CTC detection limit of 6 cells for gastric cancer.
- Out of 81 blood specimens, 38 showed visible cell growth, with 5 forming colonies.
- A final CTC detection rate of 16.0% was achieved, with positive markers identified.
Conclusions:
- Conditionally reprogrammed cell (CRC) culture shows promise for detecting circulating tumor cells.
- This method may aid in evaluating metastatic cancer cells in patient circulation.
- Further validation is warranted for clinical application.
